Meeting
2020 ASCO Virtual Scientific Program
A phase II study of BP1001 (liposomal Grb2 antisense oligonucleotide) in patients with hematologic malignancies.
Authors
Maro Ohanian
The University of Texas MD Anderson Cancer Center, Houston, TX
Maro Ohanian , Tara L. Lin , Michael Craig , Apurv Agrawal , Kathleen Halka , Ana Tari Ashizawa , Jorge E. Cortes , Gail J. Roboz
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track
Hematologic Malignancies
Sub Track
Acute Leukemia
Clinical Trial Registration Number
NCT02781883
Citation
J Clin Oncol 38: 2020 (suppl; abstr TPS7561)
DOI
10.1200/JCO.2020.38.15_suppl.TPS7561
Abstract #
TPS7561
Poster Bd #
334
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Phase II trial assessing safety and preliminary efficacy of high-dose intravenous ascorbic acid in patients with TET2-mutant clonal cytopenias of undetermined significance.
First Author: Zhuoer Xie
Poster
2020 ASCO Virtual Scientific Program
A phase II study of MT-3724, a novel CD20-targeting engineered toxin body, to evaluate safety, pharmacodynamics, and efficacy in subjects with relapsed or refractory diffuse large B-cell lymphoma.
First Author: Adolfo Enrique Diaz Duque
Poster
2018 ASCO Annual Meeting
Safety and efficacy of GVD and anti-PD-1 (SHR-1210) regimen with or without low-dose decitabine priming for refractory bulky and aggressive primary mediastinal large B-cell lymphoma.
First Author: Wenying Zhang
Poster
2018 ASCO Annual Meeting
A phase 2 study to evaluate the safety and efficacy of Intratumoral (IT) injection of the TLR9 agonist IMO-2125 (IMO) in combination with ipilimumab (ipi) in PD-1 inhibitor refractory melanoma.
First Author: Adi Diab